SABCS 2020 Wrap-Up

Breast cancer and its treatment impacts sexual health, which is an important topic for patients and clinicians to be able to address throughout the treatment process.

The DESTINY-Breast05 trial will help researchers understand the potential benefit of Enhertu (trastuzumab deruxtecan), a powerful potential treatment of patients with breast cancer with residual invasive disease after receiving chemotherapy.

Panelists discuss the challenges of the pandemic and its impact on the risk for pandemic-related disruptions in cancer care, breast cancer diagnosis, timing and choice of treatment, and mental health.

Minority women need timely, high-quality access to care, as delays in diagnosis and treatment may be fatal. Patients and clinicians need to work together to overcome obstacles, so they can gain access to the best screening, genetic testing, and treatments through clinical trials.

In patients with HER2-expressing metastatic breast cancer, Enhertu (trastuzumab deruxtecan) plus Opdivo (nivolumab) demonstrated antitumor activity consistent with previous studies of Enhertu and had an acceptable safety profile in this short-term analysis.

For patients with breast cancer, adhering to a diabetes risk reduction diet improved survival when compared with patients who did not follow this diet.

To reduce depressive symptoms, behavioral intervention techniques of mindfulness mediation and survivorship education are helpful, according to results from a recent randomized, controlled clinical trial.